30 results on '"van der Meijden, Edith D."'
Search Results
2. Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY
- Author
-
Kretschmann, Sascha, Herda, Stefanie, Bruns, Heiko, Russ, Josefine, van der Meijden, Edith D., Griffioen, Ursula Schlotzer-SchrehardMarieke, Na, Il- Kang, Mackensen, Andreas, and Kremer, Anita N.
- Subjects
Protein-protein interactions ,Antigens ,Protein binding ,Genetic research ,B cells ,Cell death ,Heat shock proteins ,Proteins ,T cells ,Biochemistry ,Tumors ,Health care industry - Abstract
Recent studies have demonstrated that [CD4.sup.+] T cells can efficiently reject MHC-II-negative tumors. This requires indirect presentation of tumor-associated antigens on surrounding antigen-presenting cells. We hypothesized that intercellular transfer of proteins is not the sole consequence of cell death-mediated protein release, but depends on heat-shock cognate protein 70 (HSC70) and its KFERQ-like binding motif on substrate proteins. Using human Y chromosome antigen DBY, we showed that mutation of one of its 2 putative binding motifs markedly diminished T cell activation after indirect presentation and reduced protein-protein interaction with HSC70. Intercellular antigen transfer was shown to be independent of cell-cell contact, but relied on engulfment within secreted microvesicles. In vivo, alterations of the homologous KFERQ-like motif in murine DBY hampered tumor rejection, T cell activation, and migration into the tumor and substantially impaired survival. Collectively, we show that intercellular antigen transfer of DBY is tightly regulated via binding to HSC70 and that this mechanism influences recognition and rejection of MHC-II-negative tumors in vivo., Introduction [CD4.sup.+] T cells play a central role in orchestrating innate and adaptive immune responses. Upon recognition of their cognate antigen in MHC-II molecules, [CD4.sup.+] T cells become activated and [...]
- Published
- 2019
- Full Text
- View/download PDF
3. Human Leukocyte Antigen–DO Regulates Surface Presentation of Human Leukocyte Antigen Class II–Restricted Antigens on B Cell Malignancies
- Author
-
Kremer, Anita N., van der Meijden, Edith D., Honders, M. Willy, Pont, Margot J., Goeman, Jelle J., Falkenburg, J.H. Frederik, and Griffioen, Marieke
- Published
- 2014
- Full Text
- View/download PDF
4. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO
- Author
-
Kremer, Anita N., van der Meijden, Edith D., Honders, Maria W., Goeman, Jelle J., Wiertz, Emmanuel J.H.J., Falkenburg, J.H. Frederik, and Griffioen, Marieke
- Published
- 2012
- Full Text
- View/download PDF
5. Identification of Phosphatidylinositol 4-Kinase Type II β as HLA Class II-Restricted Target in Graft versus Leukemia Reactivity
- Author
-
Griffioen, Marieke, van der Meijden, Edith D., Slager, Elisabeth H., Honders, M. Willy, Rutten, Caroline E., van Luxemburg-Heijs, Simone A. P., von dem Borne, Peter A., van Rood, Johannes J., Willemze, Roel, and Falkenburg, J. H. Frederik
- Published
- 2008
- Full Text
- View/download PDF
6. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4 + T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
- Author
-
Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., van der Meijden, Edith D., Griffioen, Marieke, Oudshoorn, Machteld, Willemze, Roel, and Falkenburg, J.H. Frederik
- Published
- 2010
- Full Text
- View/download PDF
7. Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity
- Author
-
Stumpf, Anita N., van der Meijden, Edith D., van Bergen, Cornelis A.M., Willemze, Roel, Falkenburg, J.H. Frederik, and Griffioen, Marieke
- Published
- 2009
- Full Text
- View/download PDF
8. Identification of phosphatidylinositol 4-kinase type II [beta] as HLA class II-restricted target in graft versus leukemia reactivity
- Author
-
Griffioen, Marieke, van der Meijden, Edith D., Slager, Elisabeth H., Honders, M. Willy, Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., von dem Borne, Peter A., van Rood, Johannes J., Willemze, Roel, and Falkenburg, J.H. Frederik
- Subjects
Immunotherapy -- Research ,Leukemia -- Care and treatment ,Lymphocytes -- Properties ,Stem cells -- Transplantation ,Stem cells -- Research ,Phosphotransferases -- Properties ,HLA class II antigens -- Properties ,Science and technology - Abstract
Patients with hematological malignancies can be successfully treated with HLA-matched T cell-depleted allogeneic stem cell transplantation (alIoSCT) and subsequent donor lymphocyte infusions (DLIs). The efficacy of DLI is mediated by donor T cells recognizing minor histocompatibility antigens (mHags) on malignant recipient cells. Because HLA class II molecules are predominantly expressed on hematopoietic cells, mHag-specific [CD4.sup.+] T cells may selectively mediate graft versus leukemia (GvL) reactivity without graft versus host disease (GvHD). In this study, we used a recombinant bacteria cDNA library for the identification of the first autosomal HLA class II (HLA-DQBl*0603)-restricted mHag LBPI4K2B-1S encoded by the broadly expressed phosphatidylinositol 4-kinase type II [beta] gene. A polyclonal [CD4.sup.+] T cell response against LB-PI4K2B-1S was demonstrated in a patient with relapsed chronic myeloid leukemia (CML) who responded to DLI after HLA-matched alIoSCT. LB-PI4K2B-1S-specific [CD4.sup.+] T cells recognized and lysed the [CD34.sup.+] CML cells of the patient and other leukemic cells as well as high HLA-DQ-expressing normal hematopoietic cells. HLA-DQ expression on normal cells of nonhematopoietic origin was moderately up-regulated by IFN-[gamma], and not sufficient for T cell recognition. We hypothesize that LB-PI4K2B-1S-specific [CD4.sup.+] T cells contributed to the antitumor response by both directly eliminating malignant cells as effector cells and stimulating [CD8.sup.+] T cell immunity as helper cells. donor lymphocyte infusions | hematological malignancies | immunotherapy | stem cell transplantation | T lymphocytes
- Published
- 2008
9. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer
- Author
-
Slager, Elisabeth H., Honders, M. Willy, van der Meijden, Edith D., van Luxemburg-Heijs, Simone A.P., Kloosterboer, Freke M., Kester, Michel G.D., Jedema, Inge, Marijt, W. A. Erik, Schaafsma, M. Ron, Willemze, Roel, and Falkenburg, J. H. Frederik
- Published
- 2006
- Full Text
- View/download PDF
10. Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity.
- Author
-
Kremer, Andreas E., Kremer, Anita N., Willam, Carsten, Völkl, Simon, Verhagen, Johan, Achenbach, Susanne, van der Meijden, Edith D., Lang, Vanessa, Aigner, Michael, Maier, Clara, Tenbusch, Matthias, Korn, Klaus, Lutzny‐Geier, Gloria, Spoerl, Silvia, Strauß, Richard, Vetter, Marcel, Überla, Klaus, Neurath, Markus F., Mackensen, Andreas, and Schiffer, Mario
- Subjects
CONVALESCENT plasma ,COVID-19 ,COVID-19 treatment ,RITUXIMAB ,CELLULAR immunity ,IMMUNOGLOBULIN producing cells - Abstract
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID‐19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key requisite in the fight against viral infections. Patients depleted of antibody‐producing B cells, such as those treated with rituximab (anti‐CD20) for hematological malignancies, lack a fundamental part of their adaptive immunity. Treatment with convalescent plasma appears to be of general benefit in this particularly vulnerable cohort. We analyzed clinical course and inflammation markers of three B‐cell‐depleted patients suffering from COVID‐19 who were treated with convalescent plasma. In addition, we measured serum antibody levels as well as peripheral blood CD38/HLA‐DR‐positive T‐cells ex vivo and CD137‐positive T‐cells after in vitro stimulation with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐derived peptides in these patients. We observed that therapy with convalescent plasma was effective in all three patients and analysis of CD137‐positive T‐cells after stimulation with SARS‐CoV‐2 peptides showed an increase in peptide‐specific T‐cells after application of convalescent plasma. In conclusion, we here demonstrate efficacy of convalescent plasma therapy in three B‐cell‐depleted patients and present data that suggest that while application of convalescent plasma elevates systemic antibody levels only transiently, it may also boost specific T‐cell responses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Human CD4+ T cells specific for dominant epitopes of SARS‐CoV‐2 Spike and Nucleocapsid proteins with therapeutic potential.
- Author
-
Verhagen, Johan, van der Meijden, Edith D., Lang, Vanessa, Kremer, Andreas E., Völkl, Simon, Mackensen, Andreas, Aigner, Michael, and Kremer, Anita N.
- Subjects
- *
T cells , *HEMATOPOIETIC stem cell transplantation , *SARS-CoV-2 , *COVID-19 , *T cell receptors - Abstract
Since December 2019, Coronavirus disease‐19 (COVID‐19) has spread rapidly throughout the world, leading to a global effort to develop vaccines and treatments. Despite extensive progress, there remains a need for treatments to bolster the immune responses in infected immunocompromised individuals, such as cancer patients who recently underwent a haematopoietic stem cell transplantation. Immunological protection against COVID‐19 is mediated by both short‐lived neutralizing antibodies and long‐lasting virus‐reactive T cells. Therefore, we propose that T cell therapy may augment efficacy of current treatments. For the greatest efficacy with minimal adverse effects, it is important that any cellular therapy is designed to be as specific and directed as possible. Here, we identify T cells from COVID‐19 patients with a potentially protective response to two major antigens of the SARS‐CoV‐2 virus, Spike and Nucleocapsid protein. By generating clones of highly virus‐reactive CD4+ T cells, we were able to confirm a set of nine immunodominant epitopes and characterize T cell responses against these. Accordingly, the sensitivity of T cell clones for their specific epitope, as well as the extent and focus of their cytokine response was examined. Moreover, using an advanced T cell receptor (TCR) sequencing approach, we determined the paired TCR‐αβ sequences of clones of interest. While these data on a limited population require further expansion for universal application, the results presented here form a crucial first step towards TCR‐transgenic CD4+ T cell therapy of COVID‐19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
- Author
-
Fuchs, Kyra J., Honders, M. Willy, van der Meijden, Edith D., Adriaans, Alwin E., van der Lee, Dyantha I., Pont, Margot J., Monajemi, Ramin, Kielbasa, Szymon M., 't Hoen, Peter A. C., van Bergen, Cornelis A. M., Falkenburg, J. H. Frederik, and Griffioen, Marieke
- Subjects
HISTOCOMPATIBILITY antigens ,GRAFT versus host reaction ,HISTOCOMPATIBILITY class I antigens ,STEM cell transplantation ,SINGLE nucleotide polymorphisms ,GENOMES ,GRAFT versus host disease - Abstract
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor T cells recognizing polymorphic peptides, which are presented on the cell surface by HLA molecules and result from single nucleotide polymorphism alleles that are disparate between patient and donor. Identification of polymorphic HLA-binding peptides, designated minor histocompatibility antigens, has been a laborious procedure, and the number and scope for broad clinical use of these antigens therefore remain limited. Here, we present an optimized whole genome association approach for discovery of HLA class I minor histocompatibility antigens. T cell clones isolated from patients who responded to donor lymphocyte infusions after HLA-matched allogeneic stem cell transplantation were tested against a panel of 191 EBV-transformed B cells, which have been sequenced by the 1000 Genomes Project and selected for expression of seven common HLA class I alleles (HLA-A
∗ 01:01, A∗ 02:01, A∗ 03:01, B∗ 07:02, B∗ 08:01, C∗ 07:01, and C∗ 07:02). By including all polymorphisms with minor allele frequencies above 0.01, we demonstrated that the new approach allows direct discovery of minor histocompatibility antigens as exemplified by seven new antigens in eight different HLA class I alleles including one antigen in HLA-A∗ 24:02 and HLA-A∗ 23:01, for which the method has not been originally designed. Our new whole genome association strategy is expected to rapidly augment the repertoire of HLA class I-restricted minor histocompatibility antigens that will become available for donor selection and clinical use to predict, follow or manipulate Graft-versus-Leukemia effect and Graft-versus-Host Disease after allogeneic stem cell transplantation. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Natural T‐cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles.
- Author
-
Kremer, Anita N., Zonneveld, Marijke I., Kremer, Andreas E., van der Meijden, Edith D., Falkenburg, J. H. Frederik, Wauben, Marca H. M., Nolte‐‘t Hoen, Esther N. M., and Griffioen, Marieke
- Abstract
Abstract: CD4 T cells play a central role as helper cells in adaptive immunity. Presentation of exogenous antigens in MHC class II by professional antigen‐presenting cells is a crucial step in induction of specific CD4 T cells in adaptive immune responses. For efficient induction of immunity against intracellular threats such as viruses or malignant transformations, antigens from HLA class II‐negative infected or transformed cells need to be transferred to surrounding antigen‐presenting cells to allow efficient priming of naive CD4 T cells. Here we show indirect antigen presentation for a subset of natural HLA class II ligands that are created by genetic variants and demonstrated that (neo)antigens can be transferred between cells by extracellular vesicles. Intercellular transfer by extracellular vesicles was not dependent on the T‐cell epitope, but rather on characteristics of the full‐length protein. This mechanism of (neo)antigen transfer from HLA class II‐negative cells to surrounding antigen‐presenting cells may play a crucial role in induction of anti‐tumor immunity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Whole Transcriptome RNA Sequencing As a Comprehensive Diagnostic Tool for Acute Myeloid Leukemia
- Author
-
Griffioen, Marieke, Arindrarto, Wibowo, Borras, Daniel M., Locher, Irene J., van Diessen, Saskia A.M.E., van der Holst, Rosalie, van der Meijden, Edith D., Honders, M. Willy, de Leeuw, Rick H., Jedema, Inge, Kroes, Wilma G.M., Knijnenburg, Jeroen, Vermaat, Joost, Valk, Peter, Janssen, Bart, de Knijff, Peter, van Bergen, Cornelis A.M., van den Akker, Erik B., 't Hoen, Peter A.C., Kielbasa, Szymon M., Laros, Jeroen F.J., and Veelken, Hendrik
- Published
- 2018
- Full Text
- View/download PDF
15. Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro
- Author
-
Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., van der Meijden, Edith D., Griffioen, Marieke, Oudshoorn, Machteld, Willemze, Roel, and Falkenburg, J. H. Frederik
- Published
- 2010
- Full Text
- View/download PDF
16. High Throughput Screening for Antibody Responses Against H-Y Antigens and Their X-Variants in Allogeneic Hematopoeietic Stem Cell Transplantation,
- Author
-
van der Griendt, Judith C, van der Meijden, Edith D, Ayoglu, Burcu, Schwenk, Jochen M, Nilsson, Peter, Falkenburg, J.H. Frederik, and Griffioen, Marieke
- Published
- 2011
- Full Text
- View/download PDF
17. Diversity of HLA Class I and Class II Restricted Minor Histocompatibility Antigens in Graft-Versus-Leukemia Reactivity.
- Author
-
Griffioen, Marieke, Honders, M. Willy, Stumpf, Anita N., van der Meijden, Edith D., van Bergen, Cornelis A.M., van Luxemburg-Heijs, Simone A.P., Lurvink, Elisabeth G.A., Willemze, Roel, and Falkenburg, J.H. Frederik
- Published
- 2009
- Full Text
- View/download PDF
18. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1 Specific T Cell Responses Showing Immunogenicity of All HLA-DPB1 Alleles
- Author
-
Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., van der Meijden, Edith D., Griffioen, Marieke, Willemze, Roelof, and Falkenburg, J.H. Frederik
- Published
- 2008
- Full Text
- View/download PDF
19. Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity.
- Author
-
Griffioen, Marieke, Honders, M. Willy, van der Meijden, Edith D., Willemze, Roelof, and Falkenburg, J.H. Frederik
- Published
- 2008
- Full Text
- View/download PDF
20. Identification of Four New HLA Class II Restricted Minor Histocompatibility Antigens Contributing to Graft Versus Leukemia Reactivity.
- Author
-
Stumpf, Anita N., van der Meijden, Edith D., van Bergen, Cornelis A.M., Willemze, Roelof, Falkenburg, J.H. Frederik, and Griffioen, Marieke
- Published
- 2008
- Full Text
- View/download PDF
21. Identification of Phosphatidylinositol 4-Kinase Type II β as the First HLA Class II Associated Minor Histocompatibility Antigen Involved in Graft Versus Leukemia Reactivity.
- Author
-
Griffioen, Marieke, van der Meijden, Edith D., Honders, M. Willy, Rutten, Caroline, van Luxemburg-Heijs, Simone A.P., von dem Borne, Peter A., Willemze, Roelof, and Falkenburg, J.H. Frederik
- Published
- 2007
- Full Text
- View/download PDF
22. HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles
- Author
-
Rutten, Caroline E., van Luxemburg-Heijs, Simone A.P., van der Meijden, Edith D., Griffioen, Marieke, Oudshoorn, Machteld, Willemze, Roel, and Falkenburg, J.H. Frederik
- Subjects
- *
HLA histocompatibility antigens , *STEM cell transplantation , *HOMOGRAFTS , *GRAFT versus host disease , *ANTIGEN presenting cells , *IMMUNE response , *T cells - Abstract
Clinical studies have indicated that HLA-DPB1 functions as a classical transplantation antigen in allogeneic stem cell transplantation. Mismatching for HLA-DPB1 was associated with an increased risk of graft-versus-host disease (GVHD), but also a decreased risk of disease relapse. However, specific HLA-DPB1 mismatches were associated with poor clinical outcome. It was suggested that this unfavorable effect was caused by a difference in immunogenicity between HLA-DPB1 alleles. To analyze whether immunogenicity of HLA-DPB1 mismatches could be predicted based on the presence or absence of specific amino acid sequences we developed a model to generate allo-HLA-DPB1 responses in vitro. We tested in total 48 different stimulator/responder combinations by stimulating CD4+ T cells from 5 HLA-DPB1 homozygous individuals with the same antigen-presenting cells transduced with different allo-HLA-DPB1 molecules. HLA-DPB1 molecules used for stimulation comprised 76% to 99% of HLA-DPB1 molecules present in different ethnic populations. We show that all HLA-DPB1 mismatches as defined by allele typing resulted in high-frequency immune responses. Furthermore, we show that crossrecognition of different HLA-DPB1 molecules is a broadly observed phenomenon. We confirm previously described patterns in crossrecognition, and demonstrate that a high degree in similarity between HLA-DPB1 molecules is predictive for crossrecognition, but not for immunogenicity. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
23. Human CD4 + T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential.
- Author
-
Verhagen J, van der Meijden ED, Lang V, Kremer AE, Völkl S, Mackensen A, Aigner M, and Kremer AN
- Subjects
- Adult, Aged, Aged, 80 and over, Amino Acid Sequence, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes virology, COVID-19 virology, Clone Cells immunology, Clone Cells virology, Coronavirus Nucleocapsid Proteins chemistry, Coronavirus Nucleocapsid Proteins genetics, Cytokines biosynthesis, Epitopes, T-Lymphocyte chemistry, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, Female, Humans, Immunization, Passive, Immunodominant Epitopes chemistry, Immunodominant Epitopes genetics, Immunodominant Epitopes immunology, Male, Middle Aged, Phosphoproteins chemistry, Phosphoproteins genetics, Phosphoproteins immunology, Receptors, Antigen, T-Cell, alpha-beta genetics, Receptors, Antigen, T-Cell, alpha-beta immunology, SARS-CoV-2 chemistry, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus genetics, COVID-19 Serotherapy, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes virology, COVID-19 immunology, COVID-19 therapy, Coronavirus Nucleocapsid Proteins immunology, SARS-CoV-2 immunology, Spike Glycoprotein, Coronavirus immunology
- Abstract
Since December 2019, Coronavirus disease-19 (COVID-19) has spread rapidly throughout the world, leading to a global effort to develop vaccines and treatments. Despite extensive progress, there remains a need for treatments to bolster the immune responses in infected immunocompromised individuals, such as cancer patients who recently underwent a haematopoietic stem cell transplantation. Immunological protection against COVID-19 is mediated by both short-lived neutralizing antibodies and long-lasting virus-reactive T cells. Therefore, we propose that T cell therapy may augment efficacy of current treatments. For the greatest efficacy with minimal adverse effects, it is important that any cellular therapy is designed to be as specific and directed as possible. Here, we identify T cells from COVID-19 patients with a potentially protective response to two major antigens of the SARS-CoV-2 virus, Spike and Nucleocapsid protein. By generating clones of highly virus-reactive CD4
+ T cells, we were able to confirm a set of nine immunodominant epitopes and characterize T cell responses against these. Accordingly, the sensitivity of T cell clones for their specific epitope, as well as the extent and focus of their cytokine response was examined. Moreover, using an advanced T cell receptor (TCR) sequencing approach, we determined the paired TCR-αβ sequences of clones of interest. While these data on a limited population require further expansion for universal application, the results presented here form a crucial first step towards TCR-transgenic CD4+ T cell therapy of COVID-19., (© 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.)- Published
- 2021
- Full Text
- View/download PDF
24. Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.
- Author
-
Bernhardt AL, Zeun J, Marecek M, Reimann H, Kretschmann S, Bausenwein J, van der Meijden ED, Karg MM, Haug T, Meintker L, Lutzny-Geier G, Mackensen A, and Kremer AN
- Subjects
- Animals, Humans, Mice, Mice, Transgenic, Antigen Presentation immunology, DNA-Binding Proteins metabolism, Immunotherapy methods, Transcription Factors metabolism
- Abstract
Background: Graft-versus-host-disease (GvHD) is a major problem in allogeneic stem cell transplantation. We previously described two types of endogenous human leukocyte antigen (HLA)-II restricted antigens depending on their behavior towards HLA-DM. While DM-resistant antigens are presented in the presence of HLA-DM, DM-sensitive antigens rely on the expression of HLA-DO-the natural inhibitor of HLA-DM. Since expression of HLA-DO is not upregulated by inflammatory cytokines, DM-sensitive antigens cannot be presented on non-hematopoietic tissues even under inflammatory conditions. Therefore, usage of CD4+ T cells directed against DM-sensitive antigens might allow induction of graft-versus-leukemia effect without GvHD. As DM-sensitivity is likely linked to low affinity peptides, it remains elusive whether DM-sensitive antigens are inferior in their immunogenicity., Methods: We created an in vivo system using a DM-sensitive and a DM-resistant variant of the same antigen. First, we generated murine cell lines overexpressing either H2-M or H2-O (murine HLA-DM and HLA-DO) to assign the two model antigens ovalbumin (OVA) and DBY to their category. Further, we introduced mutations within the two T-cell epitopes and tested the effect on DM-sensitivity or DM-resistance. Furthermore, we vaccinated C57BL/6 mice with either variant of the epitope and measured expansion and reactivity of OVA-specific and DBY-specific CD4+ T cells., Results: By testing T-cell recognition of OVA and DBY on a murine B-cell line overexpressing H2-M and H2-O, respectively, we showed that OVA leads to a stronger T-cell activation in the presence of H2-O demonstrating its DM-sensitivity. In contrast, the DBY epitope does not rely on H2-O for T-cell activation indicating DM-resistance. By introducing mutations within the T-cell epitopes we could generate one further DM-sensitive variant of OVA and two DM-resistant counterparts. Likewise, we designed DM-resistant and DM-sensitive variants of DBY. On vaccination of C57BL/6 mice with either epitope variant we measured comparable expansion and reactivity of OVA-specific and DBY-specific T-cells both in vivo and ex vivo. By generating T-cell lines and clones of healthy human donors we showed that DM-sensitive antigens are targeted by the natural T-cell repertoire., Conclusion: We successfully generated DM-sensitive and DM-resistant variants for two model antigens. Thereby, we demonstrated that DM-sensitive antigens are not inferior to their DM-resistant counterpart and are therefore interesting tools for immunotherapy after allogeneic stem cell transplantation., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
25. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
- Author
-
Reimann H, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Niazi K, Rabizadeh S, Spilman P, Mackensen A, Ruebner M, Hein A, Beckmann MW, van der Meijden ED, Bausenwein J, Kretschmann S, Griffioen M, Schlom J, Gulley JL, Lee KL, Hamilton DH, Soon-Shiong P, Fasching PA, and Kremer AN
- Subjects
- Female, Humans, Antigens, Neoplasm genetics, Breast Neoplasms genetics, Histocompatibility Antigens Class I immunology, Immunotherapy methods
- Abstract
Background: Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cell identification and validation program that supports the development of next-generation immunotherapies., Methods: Using GPS Cancer, NantOmics research, and The Cancer Genome Atlas databases, we developed a novel bioinformatic-based approach which assesses mutational load, neoepitope expression, human leukocyte antigen (HLA)-binding prediction, and in vitro confirmation of T-cell recognition to preferentially identify targetable neoepitopes. This program was validated by application to a BC cell line and confirmed using tumor biopsies from two patients with BC enrolled in the Tumor-Infiltrating Lymphocytes and Genomics (TILGen) study., Results: The antigenicity and HLA-A2 restriction of the BC cell line predicted neoepitopes were determined by reactivity of T cells from HLA-A2-expressing healthy donors. For the TILGen subjects, tumor-infiltrating lymphocytes (TILs) recognized the predicted neoepitopes both as peptides and on retroviral expression in HLA-matched Epstein-Barr virus-lymphoblastoid cell line and BC cell line MCF-7 cells; PCR clonotyping revealed the presence of T cells in the periphery with T-cell receptors for the predicted neoepitopes. These high-avidity immune responses were polyclonal, mutation-specific and restricted to either HLA class I or II. Interestingly, we observed the persistence and expansion of polyclonal T-cell responses following neoadjuvant chemotherapy., Conclusions: We demonstrate our neoepitope prediction program allows for the successful identification of neoepitopes targeted by TILs in patients with BC, providing a means to identify tumor-specific immunogenic targets for individualized treatment, including vaccines or adoptively transferred cellular therapies., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
26. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.
- Author
-
Pont MJ, Oostvogels R, van Bergen CAM, van der Meijden ED, Honders MW, Bliss S, Jongsma MLM, Lokhorst HM, Falkenburg JHF, Mutis T, Griffioen M, and Spaapen RM
- Subjects
- Humans, Epitopes, T-Lymphocyte immunology, Leukemia immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
MHC-bound peptides from aberrant proteins may be a specific immunotherapeutic target on cancer cells. Because of difficulties in identifying such antigens, viral or model antigens have so far been used to study their biological relevance. We here identify a naturally existing human T-cell epitope derived from a truncated protein. The antigenic peptide is derived from the gene TTK only through an alternative transcript containing a premature termination codon that may target the transcript for nonsense-mediated decay (NMD). This antigen is recognized by HLA-A*02:01-restricted CD8
+ T cells derived from an allotransplanted leukemia patient. Functional analyses showed that these T cells failed to recognize several HLA-matched primary leukemic cells that expressed the alternative TTK transcript. Conventional antigen processing and presentation were not affected, suggesting that leukemic cells modify the generation of antigens processed from aberrant proteins. This natural TTK epitope provides insights in the source of transcripts producing antigenic epitopes in healthy and leukemic cells. Our data underscore potential pitfalls of targeting NMD-derived or other unconventionally generated epitopes as immunotherapeutic approach., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
27. Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.
- Author
-
Pont MJ, van der Lee DI, van der Meijden ED, van Bergen CA, Kester MG, Honders MW, Vermaat M, Eefting M, Marijt EW, Kielbasa SM, Hoen PA, Falkenburg JH, and Griffioen M
- Subjects
- Amino Acid Sequence, Base Sequence, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, Female, HLA-B15 Antigen genetics, HLA-B15 Antigen immunology, Hematopoietic Stem Cell Transplantation, Humans, Integrin beta3 chemistry, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive immunology, Minor Histocompatibility Antigens chemistry, Minor Histocompatibility Antigens immunology, Peptides genetics, Peptides immunology, T-Lymphocytes, Transplantation, Homologous, Alternative Splicing, Gene Expression Profiling, Integrin beta3 genetics, Minor Histocompatibility Antigens genetics, Whole Genome Sequencing
- Abstract
Purpose: In HLA-matched allogeneic hematopoietic stem cell transplantation (alloSCT), donor T cells recognizing minor histocompatibility antigens (MiHAs) can mediate desired antitumor immunity as well as undesired side effects. MiHAs with hematopoiesis-restricted expression are relevant targets to augment antitumor immunity after alloSCT without side effects. To identify therapeutic MiHAs, we analyzed the in vivo immune response in a patient with strong antitumor immunity after alloSCT., Experimental Design: T-cell clones recognizing patient, but not donor, hematopoietic cells were selected for MiHA discovery by whole genome association scanning. RNA-sequence data from the GEUVADIS project were analyzed to investigate alternative transcripts, and expression patterns were determined by microarray analysis and qPCR. T-cell reactivity was measured by cytokine release and cytotoxicity., Results: T-cell clones were isolated for two HLA-B*15:01-restricted MiHA. LB-GLE1-1V is encoded by a nonsynonymous SNP in exon 6 of GLE1 For the other MiHAs, an associating SNP in intron 3 of ITGB2 was found, but no SNP disparity was present in the normal gene transcript between patient and donor. RNA-sequence analysis identified an alternative ITGB2 transcript containing part of intron 3. qPCR demonstrated that this transcript is restricted to hematopoietic cells and SNP-positive individuals. In silico translation revealed LB-ITGB2-1 as HLA-B*15:01-binding peptide, which was validated as hematopoietic MiHA by T-cell experiments., Conclusions: Whole genome and transcriptome analysis identified LB-ITGB2-1 as MiHAs encoded by an alternative transcript. Our data support the therapeutic relevance of LB-ITGB2-1 and illustrate the value of RNA-sequence analysis for discovery of immune targets encoded by alternative transcripts. Clin Cancer Res; 22(16); 4185-96. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
28. Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.
- Author
-
Kremer AN, van der Griendt JC, van der Meijden ED, Honders MW, Ayoglu B, Schwenk JM, Nilsson P, Falkenburg JH, and Griffioen M
- Subjects
- Allografts, B-Lymphocytes metabolism, B-Lymphocytes pathology, CD4-Positive T-Lymphocytes metabolism, CD4-Positive T-Lymphocytes pathology, Female, Focal Adhesion Kinase 2 genetics, Focal Adhesion Kinase 2 metabolism, Graft vs Host Disease enzymology, Graft vs Host Disease genetics, Graft vs Host Disease pathology, Histocompatibility Antigens Class II genetics, Histocompatibility Antigens Class II immunology, Histocompatibility Antigens Class II metabolism, Humans, Immunoglobulin G blood, Isoantibodies blood, Male, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, Focal Adhesion Kinase 2 immunology, Graft vs Host Disease immunology, Hematopoietic Stem Cell Transplantation, Immunoglobulin G immunology, Isoantibodies immunology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive enzymology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive immunology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy
- Abstract
It is well known that allo-reactive T cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (alloSCT). Allo-reactive CD4(+) T cells can mediate direct cytolysis, but may also stimulate production of IgG antibodies as helper cells. Immune complexes may subsequently be processed and presented by professional antigen presenting cells and stimulate induction of specific CD8(+) T cells. As such, proteins targeted in coordinated T- and B-cell responses may represent a class of immunodominant antigens in clinical responses after alloSCT. We previously identified LB-PTK2B-1T as HLA class II restricted polymorphic antigen in a patient treated with donor lymphocyte infusion for relapsed chronic myeloid leukemia after HLA-matched alloSCT. Since PTK2B has also been described as antibody target, we here investigated whether a coordinated T- and B-cell response against PTK2B was induced. Patient serum before and after alloSCT and donor lymphocyte infusion (DLI) was screened for antibodies, and we indeed observed development of a humoral immune response against PTK2B. Antibodies against PTK2B were only found after DLI and, in contrast to the CD4(+) T cells, recognized a monomorphic region of the protein. To our knowledge, this is the first description of a coordinated allo-reactive CD4(+) T-cell and auto-reactive antibody response against an autosomal antigen.
- Published
- 2014
- Full Text
- View/download PDF
29. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
- Author
-
Griffioen M, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Lurvink EG, Kester MG, van Bergen CA, and Falkenburg JH
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Female, Gene Expression Profiling, Gene Expression Regulation, Gene Library, Hematopoietic Stem Cell Transplantation, Humans, Leukemia genetics, Leukemia immunology, Leukemia therapy, Middle Aged, Polymorphism, Single Nucleotide, T-Lymphocytes immunology, T-Lymphocytes metabolism, Transplantation, Homologous, Graft vs Host Disease genetics, Graft vs Host Disease immunology, HLA-B40 Antigen genetics, HLA-B40 Antigen immunology, Minor Histocompatibility Antigens genetics, Minor Histocompatibility Antigens immunology
- Abstract
Background: Patients with hematologic malignancies can be successfully treated with donor lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation. The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor histocompatibility antigens. T cells recognizing hematopoietic restricted minor histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas broadly-expressed antigens may be targeted in graft-versus-host disease., Design and Methods: We analyzed in detail CD8(+) T-cell immunity in a patient with relapsed chronic myelogenous leukemia who responded to donor lymphocyte infusion with minimal graft-versus-host disease of the skin. CD8(+) T-cell clones specific for 4 HLA-B*40:01 restricted minor histocompatibility antigens were isolated which were identified by screening a plasmid cDNA library and whole genome association scanning. Detailed T-cell reactivity and monitoring experiments were performed to estimate the clinical and therapeutic relevance of the novel antigens., Results: Three antigens were demonstrated to be expressed on primary leukemic cells of various origins as well as subtypes of non-malignant hematopoietic cells, whereas one antigen was selectively recognized on malignant hematopoietic cells with antigen presenting cell phenotype. Skin derived fibroblasts were only recognized after pre-treatment with IFN-γ by two T-cell clones., Conclusions: Our data show evidence for different roles of the HLA-B*40:01 restricted minor histocompatibility antigens in the onset and execution of the anti-tumor response. All antigens may have contributed to a graft-versus-leukemia effect, and one minor histocompatibility antigen (LB-SWAP70-1Q) has specific therapeutic value based on its in vivo immunodominance and strong presentation on leukemic cells of various origins, but absence of expression on cytokine-treated fibroblasts.
- Published
- 2012
- Full Text
- View/download PDF
30. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.
- Author
-
Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ, Kester MG, Mulder A, Willemze R, Falkenburg JH, and Griffioen M
- Subjects
- Anemia, Refractory blood, Anemia, Refractory etiology, Anemia, Refractory surgery, CD8-Positive T-Lymphocytes immunology, Cells, Cultured, Epitopes, T-Lymphocyte genetics, Epitopes, T-Lymphocyte immunology, Female, Genome, Human genetics, Hematopoietic Stem Cell Transplantation methods, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery, Male, Myelodysplastic Syndromes complications, Polymerase Chain Reaction, Sequence Analysis, DNA, Transplantation, Homologous, CD8-Positive T-Lymphocytes metabolism, Genome-Wide Association Study methods, Minor Histocompatibility Antigens genetics, Polymorphism, Single Nucleotide
- Abstract
Patients with malignant diseases can be effectively treated with allogeneic hematopoietic stem cell transplantation (allo-SCT). Polymorphic peptides presented in HLA molecules, the so-called minor histocompatibility antigens (MiHA), play a crucial role in antitumor immunity as targets for alloreactive donor T cells. Identification of multiple MiHAs is essential to understand and manipulate the development of clinical responses after allo-SCT. In this study, CD8+ T-cell clones were isolated from leukemia patients who entered complete remission after allo-SCT, and MiHA-specific T-cell clones were efficiently selected for analysis of recognition of a panel of EBV-transformed B cells positive for the HLA restriction elements of the selected T-cell clones. One million single nucleotide polymorphisms (SNP) were determined in the panel cell lines and investigated for matching with the T-cell recognition data by whole genome association scanning (WGAs). Significant association with 12 genomic regions was found, and detailed analysis of genes located within these genomic regions revealed SNP disparities encoding polymorphic peptides in 10 cases. Differential recognition of patient-type, but not donor-type, peptides validated the identification of these MiHAs. Using tetramers, distinct populations of MiHA-specific CD8+ T cells were detected, demonstrating that our WGAs strategy allows high-throughput discovery of relevant targets in antitumor immunity after allo-SCT., (Copyright © 2010 AACR.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.